Marquette Asset Management, LLC Satsuma Pharmaceuticals, Inc. Transaction History

Marquette Asset Management, LLC

  • $629 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 12, 2023
BUY
$0.61 - $5.06 $47,916 - $397,468
78,551 New
78,551 $0

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Marquette Asset Management, LLC Portfolio

Follow Marquette Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marquette Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Marquette Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email